LIANY
Price:
$0.427
Market Cap:
$46.42M
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Cro...[Read more]
Industry
Biotechnology
IPO Date
2021-11-01
Stock Exchange
OTC
Ticker
LIANY
According to LianBio’s latest financial reports and current stock price. The company's current ROE is 73.99%. This represents a change of 757.20% compared to the average of 8.63% of the last 4 quarters.
The mean historical ROE of LianBio over the last ten years is -34.22%. The current 73.99% ROE has changed -316.19% with respect to the historical average. Over the past ten years (40 quarters), LIANY's ROE was at its highest in in the December 2023 quarter at 66.02%. The ROE was at its lowest in in the September 2021 quarter at -23.67%.
Average
-34.22%
Median
-55.60%
Minimum
-64.46%
Maximum
53.53%
Discovering the peaks and valleys of LianBio ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 3.63%
Maximum Annual ROE = 53.53%
Minimum Annual Increase = -226.29%
Minimum Annual ROE = -64.46%
Year | ROE | Change |
---|---|---|
2023 | 53.53% | -226.29% |
2022 | -42.39% | -23.75% |
2021 | -55.60% | -13.75% |
2020 | -64.46% | 3.63% |
The current ROE of LianBio (LIANY) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-14.82%
5-year avg
-34.22%
10-year avg
-34.22%
LianBio’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like LianBio using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like LianBio or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is LianBio's ROE?
How is the ROE calculated for LianBio (LIANY)?
What is the highest ROE for LianBio (LIANY)?
What is the 3-year average ROE for LianBio (LIANY)?
What is the 5-year average ROE for LianBio (LIANY)?
How does the current ROE for LianBio (LIANY) compare to its historical average?